Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
Thrombopoietin receptor agonist | Thrombopoietin receptor agonist | ||
| − | |||
| − | |||
==Preliminary data== | ==Preliminary data== | ||
| + | ===[[Autoimmune thrombocytopenic purpura (ITP)]]=== | ||
<span | <span | ||
style="background:#00CD00; | style="background:#00CD00; | ||
Revision as of 00:32, 26 November 2014
Mechanism of action
Thrombopoietin receptor agonist
Preliminary data
Autoimmune thrombocytopenic purpura (ITP)
Randomized Phase II, >20 per arm
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
Also known as
YM477, AKR 501